Reversibility of structural and functional damage in a model of advanced diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 24, Issue 7, 2013, Pages 1088-1102

  Pichaiwong, Warangkana ^a   Hudkins, Kelly L ^a   Wietecha, Tomasz ^a   Nguyen, Tri Q ^a   Tachaudomdach, Chiraporn ^a   Li, Wei ^a   Askari, Bardia ^a   Kobayashi, Takahisa ^a   O'Brien, Kevin D ^a   Pippin, Jeffrey W ^b   Shankland, Stuart J ^b   Alpers, Charles E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; ENALAPRIL; HYDRALAZINE; LEPTIN; LOSARTAN; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE SEVERITY; EPITHELIUM CELL; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; LEPTIN DEFICIENCY; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84879979598     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012050445     Document Type: Article

References (57)

1. US Renal Data System: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
2. US Renal Data System: 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, 2007, pp 239-254
3. Atkins RC, Zimmet P: Diabetic kidney disease: Act now or pay later. Nephrol Dial Transplant 25: 331-333, 2010
4. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532-2539, 2011
5. Reutens A, Prentice L, Atkins R: The epidemiology of diabetic kidney disease. In: The Epidemiology of Diabetes Mellitus, edited by Ekoe J, Chichester, Wiley, 2008
6. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49: S12-S154, 2007
7. Nelson RG, Tuttle KR: Prevention of diabetic kidney disease: Negative clinical trials with renin-Angiotensin system inhibitors. Am J Kidney Dis 55: 426-430, 2010
8. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361: 40-51, 2009
9. Jefferson JA, Shankland SJ, Pichler RH: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int 74: 22-36, 2008
10. Hudkins KL, Pichaiwong W, Wietecha T, Kowalewska J, Banas MC, Spencer MW, Muhlfeld A, Koelling M, Pippin JW, Shankland SJ, Askari B, Rabaglia ME, Keller MP, Attie AD, Alpers CE: BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 21: 1533-1542, 2010
11. Alpers CE, Hudkins KL: Mouse models of diabetic nephropathy. Curr Opin Nephrol Hypertens 20: 278-284, 2011
12. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, SmithiesO, Susztak K, Takahashi N, Takahashi T; Animal Models of Diabetic Complications Consortium: Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503-2512, 2009
13. Taniguchi Y, Pippin JW, Hagmann H, Krofft RD, Chang AM, Zhang J, Terada Y, Brinkkoetter P, Shankland SJ: Both cyclin I and p35 are required for maximal survival benefit of cyclin-dependent kinase 5 in kidney podocytes. AmJ Physiol Renal Physiol 302: F1161-F1171, 2012
14. Nicholas SB, Basgen JM, Sinha S: Using stereologic techniques for podocyte counting in themouse: Shifting the paradigm. Am J Nephrol 33[Suppl 1]: 1-7, 2011
15. Bai XY, Basgen JM: Podocyte number in the maturing rat kidney. Am J Nephrol 33: 91-96, 2011
16. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL: Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305, 1998
17. Fioretto P, SteffesMW, Sutherland DE, Goetz FC,MauerM: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998
18. Fioretto P, Sutherland DE, Najafian B, Mauer M: Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 69: 907-912, 2006
19. Mauer SM, Sutherland DE, Steffes MW, Leonard RJ, Najarian JS, Michael AF, Brown DM: Pancreatic islet transplantation. Effects on the glomerular lesions of experimental diabetes in the rat. Diabetes 23: 748-753, 1974
20. Steffes MW, Vernier RL, Brown DM, Basgen JM, Mauer SM: Diabetic glomerulopathy in the uninephrectomized rat resists amelioration following islet transplantation. Diabetologia 23: 347-353, 1982
21. Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: Past, present, and future. Kidney Int 72: 26-36, 2007
22. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997
23. Eremina V,Cui S,GerberH, FerraraN,Haigh J,Nagy A, EmaM, Rossant J, Jothy S, Miner JH, Quaggin SE: Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am SocNephrol 17: 724-735, 2006
24. Eremina V, Jefferson JA, Kowalewska J, Hochster H,HaasM,Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008
25. Eremina V, Baelde HJ, Quaggin SE: Role of the VEGF-A signaling pathway in the glomerulus: Evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 106: 32-37, 2007
26. Quaggin SE, Coffman TM: Toward a mouse model of diabetic nephropathy: Is endothelial nitric oxide synthase the missing link? J Am Soc Nephrol 18: 364-366, 2007
27. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I: Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J AmSoc Nephrol 16: 1013-1023, 2005
28. Stout LC, Kumar S, Whorton EB: Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule. HumPathol 24: 77-89, 1993
29. Najafian B, Alpers CE, Fogo AB: Pathology of human diabetic nephropathy. Contrib Nephrol 170: 36-47, 2011
30. Shankland SJ: The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147, 2006
31. Appel D, Kershaw DB, Smeets B, Yuan G, Fuss A, Frye B, Elger M, Kriz W, Floege J, Moeller MJ: Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 20: 333-343, 2009
32. Ronconi E, Sagrinati C, AngelottiML, Lazzeri E,Mazzinghi B, Ballerini L, Parente E, Becherucci F, Gacci M, Carini M, Maggi E, Serio M, Vannelli GB, Lasagni L, Romagnani S, Romagnani P: Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol 20: 322-332, 2009
33. Lasagni L, Romagnani P: Glomerular epithelial stem cells: The good, the bad, and the ugly. J Am Soc Nephrol 21: 1612-1619, 2010
34. Giacco F, Brownlee M: Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010
35. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454, 2008
36. Decleves AE, Sharma K: New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 6: 371-380, 2010
37. Eid AA, Gorin Y, Fagg BM, Maalouf R, Barnes JL, Block K, Abboud HE: Mechanisms of podocyte injury in diabetes: Role of cytochrome P450 and NADPH oxidases. Diabetes 58: 1201-1211, 2009
38. Susztak K, Raff AC, SchifferM, Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006
39. Najafian B, Mauer M: Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract 83: 1-8, 2009
40. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA; Renal Pathology Society: Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21: 556-563, 2010
41. Clee SM, Attie AD: The genetic landscape of type 2 diabetes in mice. Endocr Rev 28: 48-83, 2007
42. Clee SM, Nadler ST, Attie AD: Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. Am J Ther 12: 491-498, 2005
43. Ranheim T, Dumke C, Schueler KL, Cartee GD, Attie AD: Interaction between BTBR and C57BL/6J genomes produces an insulin resistance syndrome in (BTBR x C57BL/6J) F1mice. Arterioscler Thromb Vasc Biol 17: 3286-3293, 1997
44. Guo S, Kowalewska J, Wietecha TA, Iyoda M,Wang L, Yi K, SpencerM, Banas M, Alexandrescu S, Hudkins KL, Alpers CE: Renin-Angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol 19: 1168-1176, 2008
45. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K: Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 21: 1288-1291, 2008
46. Whitesall SE, Hoff JB, Vollmer AP, D'Alecy LG: Comparison of simultaneous measurement of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods. Am J Physiol Heart Circ Physiol 286: H2408-H2415, 2004
47. Alpers CE, Seifert RA, Hudkins KL, Johnson RJ, Bowen-Pope DF: Developmental patterns of PDGF B-chain, PDGF-receptor, and alphaactin expression in human glomerulogenesis. Kidney Int 42: 390-399, 1992
48. Taneda S, Segerer S, Hudkins KL, Cui Y,WenM, SegererM,WenerMH, Khairallah CG, Farr AG, Alpers CE: Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice. Am J Pathol 159: 2355-2369, 2001
49. TakemotoM, Asker N, Gerhardt H, Lundkvist A, Johansson BR, Saito Y, Betsholtz C: A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799-805, 2002
50. Taneda S, Hudkins KL, Cui Y, Farr AG, Alpers CE, Segerer S: Growth factor expression in amurinemodel of cryoglobulinemia. Kidney Int 63: 576-590, 2003
51. Taneda S, Hudkins KL, Muhlfeld AS, Kowalewska J, Pippin JW, Shankland SJ, Alpers CE: Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis. J Am Soc Nephrol 19: 243-251, 2008
52. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S: Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem 266: 18731-18736, 1991
53. Alpers CE,Hudkins KL, Pritzl P, Johnson RJ:Mechanisms of clearance of immune complexes from peritubular capillaries in the rat. Am J Pathol 139: 855-867, 1991
54. Sanden SK,Wiggins JE, GoyalM, Riggs LK,Wiggins RC: Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 14: 2484-2493, 2003
55. Weibel ER: Practical Methods for Biological Morphometry, London, Academic Press, 1979, pp. 40-116).
56. Changsirikulchai S, Hudkins KL, Goodpaster TA, Volpone J, Topouzis S, Gilbertson DG, Alpers CE: Platelet-derived growth factor-D expression in developing and mature human kidneys. Kidney Int 62: 2043-2054, 2002
57. Banas MC, Banas B, Hudkins KL, Wietecha TAIyoda M, Bock E, Hauser P, Pippin JW, Shankland SJ, Smith KD, Stoelcker B, Liu G, Gröne HJ, Kramer BK, Alpers CE: TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19: 704-713, 2008